The FDA has approved Jentadueto XR (linagliptin and metformin hydrochloride extended-release) tablets, from Boehringer Ingelheim and Eli Lilly, for the...
The EMA's CHMP recommend approval of Jentadueto (linagliptin plus metformin), from Boehringer, alongside diet and exercise to improve glycaemic control...
The EU has approved Jentadueto (linagliptin plus metformin), from Boehringer, for use alongside diet and exercise to improve glycaemic control...
Jentadueto is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control: • in patients inadequately controlled on their maximally tolerated dose of metformin alone • in combination with other medicinal products for the treatment of diabetes, including insulin, in patients inadequately controlled with metformin and these medicinal products • in patients already being treated with the combination of linagliptin and metformin as separate tablets. (see sections 4.4, 4.5 and 5.1 for available data on different combinations).
The Federal Patent Court in Germany has found the formulation patent protecting Seroquel XR (quetiapine fumarate) prolonged-release tablets � marketed...
The FDA has approved Quillivant XR (methylphenidate hydrochloride) from Next Wave Pharma for extended-release oral suspension for treatment of Attention...
The FDA has informed Veloxis of the tentative approval of Envarsus XR (tacrolimus extended relief) for Transplant Rejection. The FDA...